Johnson & Johnson’s (JNJ) Interventional Solutions business reported solid growth in the third quarter. JNJ’s Interventional Solutions segment generated third-quarter net revenues of $653.0 million, compared to $553.0 million in the third quarter of 2017, reflecting ~18.1% YoY growth. Johnson & Johnson’s Interventional Solutions segment reported ~19.4% YoY operational growth.
In the US and international markets, JNJ’s Interventional Solutions segment generated third-quarter revenues of $320.0 million and $333.0 million, respectively, reflecting ~14.7% and 21.5% YoY growth. In the international markets, JNJ’s Interventional Solutions segment reported ~24.1% YoY operational growth.
Johnson & Johnson’s (JNJ) Interventional Solutions segment generated revenues of $1.96 billion in the first nine months of 2018 compared to $1.68 billion in the first nine months of 2017, reflecting ~17.0% YoY growth.
In the US market and international markets, the Interventional Solutions segment reported net revenues of $947.0 million and $1.0 billion, respectively, reflecting ~12.3% and ~21.8% YoY growth.
The strong growth in sales of electrophysiology products was a primary factor in the growth of JNJ’s Interventional Solutions segment. The increase in the atrial fibrillation procedure led to the demand for electrophysiology products. Solid growth of JNJ’s ThermoCool SmartTouch SF Contact Force Sensing Catheter and diagnostic catheter significantly boosted the growth of the Interventional Solutions business.
Among Johnson & Johnson’s (JNJ) peers in the interventional solutions market, Merit Medical Systems (MMSI) and Boston Scientific (BSX) reported revenues of $224.81 million and $2.5 billion, respectively, in the second quarter of 2018, reflecting ~20.51% and ~10.32% YoY growth.
Wall Street analysts expect Merit Medical and Boston Scientific (BSX) to report net revenues of $216.94 million and $2.4 billion in the third quarter.